Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement